APOBEC1 and atherosclerosis: To test whether TIC better protects against atherosclerosis than does CLO when both are given in the doses that equally inhibit platelet aggregation, we performed a standard atherosclerosis assay by administering no drug (CTL), 25 mg/kg/day of CLO, or 180 mg/kg/day of TIC for 16 weeks to Ldlr-/- Apobec1-/- mice that were placed on a HFD.